Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

New Opioid Labeling Further Constrains Use, Urges Prescribing Only By Docs ‘Knowledgeable’ About Risks

Apr 18 2023

• By Derrick Gingery

opioids — The REMS changes mandating mail-back disposal envelopes are expected to be approved in 2024. • Source: Shutterstock

Related Content

Opioid Long-Term Effectiveness: FDA Postmarket Trial Design Offers ‘Best Compromise’

Apr 18 2023

Califf Hints At Labeling Changes For Opioids And Chronic Pain

Feb 23 2023

Opioid Prescribing Guidelines From US FDA Could Be A While After NASEM Report

Dec 20 2019

Opioid Blister Packs Need Study Before Mandate, Groups Urge

Aug 12 2019

Opioid Diversion, Postal Carrier Dangers Among Industry Concerns With Mail-Back Envelope Requirement

Jul 20 2022

‘Opioids’ Is Missing From The US FDA’s Overdose Prevention Framework Title On Purpose

Sep 14 2022

New Opioid Approval Standard Intended To Drive Development Into Other Therapeutics

Sep 07 2022

Califf Says Opioid Labeling Changes, Withdrawals Still Possible

Apr 13 2022

Green Light For First OTC Naloxone In US After FDA Raises Caution Flag During Advisory Panel

Mar 30 2023

Additional Topics

United States Drug Safety Post Market Regulation & Studies Regulation Neurology BioPharmaceutical

More from Drug Safety

More from Pink Sheet

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window